Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed

NCT01133158 is registered in ClinicalTrials.gov with Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea as lead sponsor.

NCT NCT01133158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01133158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed
Lead sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
July 31, 2016
Enrollment
61 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma